- US-listed companies
- Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd.ENLV
Market cap
P/E ratio
Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | |
Research and development expenses, net (note 16a) | 4 | 8 | 9 | 3 | - | 6 | 6 | 13 | 19 |
General and administrative expenses (note 16b) | 3 | 7 | 6 | 3 | - | 3 | 4 | 6 | 7 |
Total operating expenses | - | - | 16 | 6 | - | 9 | 10 | 19 | 26 |
Operating (loss) | -7 | -15 | -16 | -6 | - | -9 | -10 | -19 | -26 |
Other income (expenses), net (note 16c) | - | - | - | - | - | - | - | 5 | -5 |
Net (loss) | -7 | -15 | -16 | -6 | -4 | -9 | -12 | -14 | -31 |
Exchange differences arising from translating financial statements from functional to presentation currency | - | - | - | - | - | 1 | 2 | 0 | - |
Total other comprehensive gain | - | - | - | - | - | 1 | 2 | 0 | - |
Total comprehensive (loss) | - | - | - | - | - | -8 | -10 | -14 | -31 |
Basic & diluted (loss) per share (in Dollars per share) | - | - | - | - | - | - | - | - | -1.69 |